Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Dec;81(8):1294–1303. doi: 10.1038/sj.bjc.6694381

Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin

C F O’Neill 1, B Koberle 2, J R W Masters 2, L R Kelland 1
PMCID: PMC2362973  PMID: 10604725

Abstract

JM216, an oral platinum drug entering into phase III clinical trial, exhibited comparable cytotoxicity to cisplatin in three human ovarian carcinoma cell lines: the sensitive (CH1), acquired resistant (CH1cisR) and intrinsically resistant (SKOV-3). Platinum accumulation and binding to DNA were similar in each of the three cell lines at equimolar doses, indicating that the resistant cell lines could tolerate higher intracellular platinum levels and platinum bound to DNA at IC50 concentrations of drug. Comparison with cisplatin demonstrated that intracellular platinum levels were marginally higher with JM216, but that platinum binding to DNA was similar for the two drugs in each of the cell lines. Each of the cell lines exhibited an ability to repair JM216 induced platinum/DNA lesions in the N-ras gene (gene-specific repair) at equitoxic concentrations of drug. However, this occurred to a greater extent in the two resistant cell lines such that by 24 h the CH1cisR and SKOV-3 had removed 72% and 67% respectively compared with approximately 32% for the CH1. Reduced gene-specific repair capacity in CH1 cells was also seen following incubation with 25 μM (or 5 μM – 2 × IC50) cisplatin, whereas the CH1cisR and SKOV-3 cell lines were repair proficient. JM216 induced apoptosis in the three cell lines following a 2h incubation with 2 × the IC50 of drug. Fluorescent microscopy of cells stained with propidium iodide showed that the detached cell population displayed typical apoptotic nuclei. Furthermore, field inversion gel electrophoresis demonstrated the presence of DNA fragments approximately 23–50 kb in size, indicative of apoptosis, in the detached cells. JM216 induced an S phase slow down in each of the three cell lines accompanied by a G2 block in the CH1 pair. Incubation with this concentration of JM216 also resulted in the induction of p53 in the CH1 and CH1cisR. These studies suggest that the relative sensitivity of the CH1 cell line to cisplatin and JM216 is at least partly attributable to a deficiency in gene-specific repair. The oral platinum drug, JM216, exerts its cytotoxic effects through the induction of apoptosis following a slow-down in S phase in both the sensitive and resistant lines. © 1999 Cancer Research Campaign

Keywords: JM216, cisplatin, gene-specific repair, apoptosis

Full Text

The Full Text of this article is available as a PDF (233.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BURTON K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J. 1956 Feb;62(2):315–323. doi: 10.1042/bj0620315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fogh J., Wright W. C., Loveless J. D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst. 1977 Feb;58(2):209–214. doi: 10.1093/jnci/58.2.209. [DOI] [PubMed] [Google Scholar]
  3. Grimaldi K. A., Bingham J. P., Souhami R. L., Hartley J. A. DNA damage by anticancer agents and its repair: mapping in cells at the subgene level with quantitative polymerase chain reaction. Anal Biochem. 1994 Oct;222(1):236–242. doi: 10.1006/abio.1994.1479. [DOI] [PubMed] [Google Scholar]
  4. Hainaut P. The tumor suppressor protein p53: a receptor to genotoxic stress that controls cell growth and survival. Curr Opin Oncol. 1995 Jan;7(1):76–82. [PubMed] [Google Scholar]
  5. Hills C. A., Kelland L. R., Abel G., Siracky J., Wilson A. P., Harrap K. R. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer. 1989 Apr;59(4):527–534. doi: 10.1038/bjc.1989.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Johnson S. W., Perez R. P., Godwin A. K., Yeung A. T., Handel L. M., Ozols R. F., Hamilton T. C. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol. 1994 Feb 11;47(4):689–697. doi: 10.1016/0006-2952(94)90132-5. [DOI] [PubMed] [Google Scholar]
  7. Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B., Craig R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991 Dec 1;51(23 Pt 1):6304–6311. [PubMed] [Google Scholar]
  8. Kelland L. R., Abel G., McKeage M. J., Jones M., Goddard P. M., Valenti M., Murrer B. A., Harrap K. R. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res. 1993 Jun 1;53(11):2581–2586. [PubMed] [Google Scholar]
  9. Kelland L. R., Mistry P., Abel G., Loh S. Y., O'Neill C. F., Murrer B. A., Harrap K. R. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res. 1992 Jul 15;52(14):3857–3864. [PubMed] [Google Scholar]
  10. Kelland L. R., Murrer B. A., Abel G., Giandomenico C. M., Mistry P., Harrap K. R. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1992 Feb 15;52(4):822–828. [PubMed] [Google Scholar]
  11. Kirby K. S., Cook E. A. Isolation of deoxyribonucleic acid from mammalian tissues. Biochem J. 1967 Jul;104(1):254–257. doi: 10.1042/bj1040254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Köberle B., Grimaldi K. A., Sunters A., Hartley J. A., Kelland L. R., Masters J. R. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer. 1997 Mar 4;70(5):551–555. doi: 10.1002/(sici)1097-0215(19970304)70:5<551::aid-ijc10>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  13. Köberle B., Payne J., Grimaldi K. A., Hartley J. A., Masters J. R. DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. Biochem Pharmacol. 1996 Dec 13;52(11):1729–1734. doi: 10.1016/s0006-2952(96)00549-7. [DOI] [PubMed] [Google Scholar]
  14. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  15. Lowe S. W., Bodis S., McClatchey A., Remington L., Ruley H. E., Fisher D. E., Housman D. E., Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science. 1994 Nov 4;266(5186):807–810. doi: 10.1126/science.7973635. [DOI] [PubMed] [Google Scholar]
  16. Lowe S. W., Ruley H. E., Jacks T., Housman D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993 Sep 24;74(6):957–967. doi: 10.1016/0092-8674(93)90719-7. [DOI] [PubMed] [Google Scholar]
  17. McIlwrath A. J., Vasey P. A., Ross G. M., Brown R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res. 1994 Jul 15;54(14):3718–3722. [PubMed] [Google Scholar]
  18. McKeage M. J., Mistry P., Ward J., Boxall F. E., Loh S., O'Neill C., Ellis P., Kelland L. R., Morgan S. E., Murrer B. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol. 1995;36(6):451–458. doi: 10.1007/BF00685793. [DOI] [PubMed] [Google Scholar]
  19. Mellish K. J., Kelland L. R., Harrap K. R. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer. 1993 Aug;68(2):240–250. doi: 10.1038/bjc.1993.322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Mellish K. J., Kelland L. R. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines. Cancer Res. 1994 Dec 1;54(23):6194–6200. [PubMed] [Google Scholar]
  21. Mistry P., Kelland L. R., Abel G., Sidhar S., Harrap K. R. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer. 1991 Aug;64(2):215–220. doi: 10.1038/bjc.1991.279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. O'Neill C. F., Ormerod M. G., Robertson D., Titley J. C., Cumber-Walsweer Y., Kelland L. R. Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex. Br J Cancer. 1996 Oct;74(7):1037–1045. doi: 10.1038/bjc.1996.486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Oberhammer F., Wilson J. W., Dive C., Morris I. D., Hickman J. A., Wakeling A. E., Walker P. R., Sikorska M. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J. 1993 Sep;12(9):3679–3684. doi: 10.1002/j.1460-2075.1993.tb06042.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Ormerod M. G., O'Neill C. F., Robertson D., Harrap K. R. Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA. Exp Cell Res. 1994 Apr;211(2):231–237. doi: 10.1006/excr.1994.1082. [DOI] [PubMed] [Google Scholar]
  25. Ormerod M. G., O'Neill C., Robertson D., Kelland L. R., Harrap K. R. cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol. 1996;37(5):463–471. doi: 10.1007/s002800050413. [DOI] [PubMed] [Google Scholar]
  26. Ormerod M. G., Orr R. M., Peacock J. H. The role of apoptosis in cell killing by cisplatin: a flow cytometric study. Br J Cancer. 1994 Jan;69(1):93–100. doi: 10.1038/bjc.1994.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Ormerod M. G., Payne A. W., Watson J. V. Improved program for the analysis of DNA histograms. Cytometry. 1987 Nov;8(6):637–641. doi: 10.1002/cyto.990080617. [DOI] [PubMed] [Google Scholar]
  28. Perego P., Giarola M., Righetti S. C., Supino R., Caserini C., Delia D., Pierotti M. A., Miyashita T., Reed J. C., Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 1996 Feb 1;56(3):556–562. [PubMed] [Google Scholar]
  29. Pestell K. E., Medlow C. J., Titley J. C., Kelland L. R., Walton M. I. Characterisation of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines. Int J Cancer. 1998 Sep 11;77(6):913–918. doi: 10.1002/(sici)1097-0215(19980911)77:6<913::aid-ijc19>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  30. Petersen L. N., Mamenta E. L., Stevnsner T., Chaney S. G., Bohr V. A. Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity. Carcinogenesis. 1996 Dec;17(12):2597–2602. doi: 10.1093/carcin/17.12.2597. [DOI] [PubMed] [Google Scholar]
  31. Poon G. K., Raynaud F. I., Mistry P., Odell D. E., Kelland L. R., Harrap K. R., Barnard C. F., Murrer B. A. Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr A. 1995 Sep 29;712(1):61–66. doi: 10.1016/0021-9673(95)00288-x. [DOI] [PubMed] [Google Scholar]
  32. Raynaud F. I., Mistry P., Donaghue A., Poon G. K., Kelland L. R., Barnard C. F., Murrer B. A., Harrap K. R. Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol. 1996;38(2):155–162. doi: 10.1007/s002800050464. [DOI] [PubMed] [Google Scholar]
  33. Sorenson C. M., Eastman A. Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res. 1988 Dec 1;48(23):6703–6707. [PubMed] [Google Scholar]
  34. Twentyman P. R., Wright K. A., Mistry P., Kelland L. R., Murrer B. A. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res. 1992 Oct 15;52(20):5674–5680. [PubMed] [Google Scholar]
  35. Vaisman A., Varchenko M., Said I., Chaney S. G. Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry. 1997 Jan 1;27(1):54–64. doi: 10.1002/(sici)1097-0320(19970101)27:1<54::aid-cyto7>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  36. Winters Z. E., Ongkeko W. M., Harris A. L., Norbury C. J. p53 regulates Cdc2 independently of inhibitory phosphorylation to reinforce radiation-induced G2 arrest in human cells. Oncogene. 1998 Aug 13;17(6):673–684. doi: 10.1038/sj.onc.1201991. [DOI] [PubMed] [Google Scholar]
  37. Yaginuma Y., Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res. 1992 Aug 1;52(15):4196–4199. [PubMed] [Google Scholar]
  38. Zaffaroni N., Silvestrini R., Orlandi L., Bearzatto A., Gornati D., Villa R. Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells. Br J Cancer. 1998 May;77(9):1378–1385. doi: 10.1038/bjc.1998.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Zhen W., Link C. J., Jr, O'Connor P. M., Reed E., Parker R., Howell S. B., Bohr V. A. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol. 1992 Sep;12(9):3689–3698. doi: 10.1128/mcb.12.9.3689. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES